Leads Biolabs to present LBL-024 first-line NSCLC cohort data in September
The PD-L1/4-1BB bispecific, already headed toward a BLA in another cancer, faces its first large first-line lung cancer readout as the Phase 2 trial keeps enrolling toward a December 2026 completion.
Executive Summary
- Leads Biolabs plans to show new first-line lung cancer data for its dual-mechanism antibody at a major oncology conference, giving investors a first public read on a tumor type outside the drug's lead indication.
- The underlying study is recruiting on schedule, with a modest enrollment increase and no completion-date slippage, so the presentation timing reflects normal trial progress rather than an operational surprise.
- The drug has already advanced to a regulatory filing stage in a different, rarer cancer type, so a positive signal in a common first-line lung cancer population would extend the mechanism's reach well beyond its original niche.
- No other program sharing this drug's dual-target mechanism is running in first-line NSCLC, leaving the September data as an isolated test of whether the approach translates to a much larger and more competitive tumor setting.
The presentation
Leads Biolabs (9887.HK) said it will present a large-cohort update on LBL-024 in first-line NSCLC at the World Conference on Lung Cancer, with the presentation window running September 1 through September 30, 2026. The data come from a first-line NSCLC substudy nested inside a broader Phase 2 trial testing LBL-024 combinations across advanced tumors, registered as NCT06783647. LBL-024 targets both PD-L1 and 4-1BB, pairing checkpoint blockade with a co-stimulatory signal in a single bispecific molecule, according to the company's own description of the drug's design. Leads+1Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology LandscapeMay 11, 2026A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]NCT06783647
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Trial status
The NSCLC substudy is Recruiting, having moved out of Not yet recruiting status in July 2025. Its enrollment target rose from 210 to 230 patients in August 2025, a 9.5% increase that the trial's own operational baseline for enrollment changes characterizes as within the routine band, not a change that signals distress. The primary completion date has not moved and stands at December 24, 2026. The trial's registered primary outcome measure is objective response rate. NCT06783647A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]NCT06783647
Why the setting matters
LBL-024's furthest-advanced program is in extrapulmonary neuroendocrine carcinoma, a rare and hard-to-treat cancer type where the company says the drug has reached BLA submission. The company also describes the drug's dose escalation reaching 25.0 mg/kg without a maximum tolerated dose or dose-limiting toxicities, and reports liver enzyme abnormalities confined to early treatment with no cumulative hepatotoxicity across a pooled population of over 600 patients treated across its programs. First-line NSCLC is a far larger and more heavily studied population than extrapulmonary neuroendocrine carcinoma, so the September data will be the first test of whether the same mechanism produces a response signal in a tumor type where checkpoint inhibitors are already standard of care. LeadsLeads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology LandscapeMay 11, 2026
The competitive field
No trial sharing LBL-024's PD-L1/4-1BB target combination is running in first-line NSCLC, leaving the drug without a direct mechanism comparator in this setting. The nearest context comes from indication-level activity in NSCLC, where competing programs test PD-1, KRAS G12C, TLR7, and neoantigen-directed mechanisms rather than the same dual-target approach, including trials from Merck Sharp & Dohme, Eikon Therapeutics, and others. That isolation makes the NSCLC cohort a standalone read on whether combining checkpoint blockade with 4-1BB co-stimulation can produce a response rate that stands out against established first-line NSCLC regimens, rather than a race against a mechanistic peer.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.